Compare OGI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | CRBU |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.3M | 138.3M |
| IPO Year | 2015 | 2021 |
| Metric | OGI | CRBU |
|---|---|---|
| Price | $0.93 | $0.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.39 | ★ $5.75 |
| AVG Volume (30 Days) | 447.7K | ★ 4.2M |
| Earning Date | 08-11-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.95 | $145.34 |
| Revenue Next Year | $30.97 | N/A |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $0.44 |
| 52 Week High | $2.24 | $3.53 |
| Indicator | OGI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 34.74 | 13.59 |
| Support Level | $0.92 | $0.44 |
| Resistance Level | $1.07 | $1.72 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 15.67 | 2.87 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.